← Back to patent-cliff list
ATR-258
Tier C — Watch / tradeATR-258
Atrogi AB
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADRB2
Indications (approved)：Overweight, Obesity, Type 2 diabetes
Regional status
US
-
EU
Phase II
2026-02-19
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ATR-258?
Approved indications include: Overweight, Obesity, Type 2 diabetes.
When does the ATR-258 patent expire?
No public expiry year is available for ATR-258 yet; this page updates once verified.
How do I get a quote for ATR-258 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29